ClinicalTrials.gg
Not yet recruitingNCT06769815HIPPIUpdated Jan 24, 2025

Host Immunity, Plasmodium and Pathogens Co-Infections

An interventional study of Blood sample and Urine sample in Malaria and Bacterial Co-infection, sponsored by Institut Pasteur. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Not applicable
Sex
All
01

Study summary

Few studies have focused on malaria co-infections, mainly caused by Plasmodium falciparum, occurring mainly in children under 5 years of age in sub-Saharan Africa. These studies have focused on malaria-associated bacterial sepsis, with an estimated prevalence of 9.1% and associated mortality of 15.0%. However, no study has documented infectious sites other than the blood compartment, considered viruses and parasites as possible causes of infection in addition to bacteria, and used molecular diagnostic methods based on PCRs, which are more sensitive. Thus, the prevalence of these co-infections and the spectrum of pathogens involved are probably underestimated, as is the impact of these co-infections on mortality. Furthermore, it has been shown that malaria infections can condition the immune cells of naturally exposed individuals, potentially leading to greater susceptibility to all types of infection. But these mechanisms have never been documented in the context of co-infections.

The WHO recommends the use of broad-spectrum antibiotics in cases of severe malaria, in addition to antimalarial drugs, as it can be difficult to differentiate clinically between severe malaria and severe bacterial infection (bacteremia, pneumonia and meningitis). Yet this empirical use of antibiotics could be contributing to an increase in antibiotic resistance. Identifying the determinants of co-infection with malaria and severe bacterial infection would enable this treatment to be better targeted.

These determinants remain undetermined as no study has considered other causes of severe bacterial infection other than bacteremia, used appropriate statistical methodology (univariate analysis only) and explored important determinants, notably the capacity of children's innate immunity to respond to severe bacterial infection.

Read the detailed description

This is a prospective multicenter longitudinal study.

The study will focus on several populations:

  • febrile children: aged between 6 and 60 months consulting ;
  • non-febrile children: aged between 6 and 60 months consulting.
  • Pregnant women.
  • newborns: those born to mothers included in the study with or without pregnancy-associated malaria.

The study will be based on :

  • Clinical and microbiological documentation of acute febrile episodes in recruited children
  • Documentation of vital status in children 3 months after recruitment
  • Ability of host cells to respond to infections.
02

Conditions studied

  • Malaria
  • Bacterial Co-infection

Keywords

  • malaria
  • co-infection
  • immune response
  • epigenetic mechanisms
  • children
  • Togo
03

In context

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 252 across 939 interventional studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Febrile children:

  • aged between 6 and 60 months
  • with a febrile episode lasting less than 7 days (axillary temperature >=37.5° Celsius)
  • whose state of health is compatible with a minimum single blood sample volume of 6.25 ml

Non-febrile children:

  • aged between 6 and 60 months
  • with axillary temperature \<37.5° Celsius
  • no clinical signs of infection at the time of inclusion
  • no infectious episode or fever for 7 days

Pregnant women :

  • giving birth in the project's partner health center
  • intending to reside in the study area during the newborn follow-up period
  • with a mono-fetal pregnancy
  • With an apparently uncomplicated delivery not requiring referral to a higher-level health facility

Newborns at delivery:

  • Born at term (determined by Ballard score)
  • whose parents or legal guardians reside in the study area during the newborn's follow-up period

Exclusion criteria

Exclusion Criteria:

For all :

  • person already participating in another biomedical research project.

For febrile and non-febrile children:

  • chronic non-infectious pathology (cancer, malnutrition, etc.)

For pregnant women

  • scheduled caesarean section for current pregnancy
  • Caesarean section in previous pregnancies
  • chronic non-infectious pathology during pregnancy (diabetes, hypertension, pre-eclampsia)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Other
    Febrile and non febrile children, pregnant women and new borns

    The study population is composed of children under the age of 5, which is also the population most at risk of malaria, living in the endemic areas of Lomé and Tsévié in Togo.

    Other: Blood sample · Other: Urine sample · Other: oropharyngeal sample · Other: Optionnal : stool sample · Other: Optionnal : cerebrospinal fluid · Other: placental biopsy

Interventions

  • OtherBlood sample

    For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.

  • OtherUrine sample

    For febrile children : 10 ml of urine

  • Otheroropharyngeal sample

    For febrile children : oropharyngeal swab sampling

  • OtherOptionnal : stool sample

    For febrile children (only as part of the care of the child) : 5g stool

  • OtherOptionnal : cerebrospinal fluid

    For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid

  • Otherplacental biopsy

    For pregnant women : placental biopsy the size of 2 rice grains

06

What researchers measure

Primary outcomes

  1. Determine the extent and microbiological spectrum of malaria co-infections in children under 5.

    the number of malaria co-infection events in febrile children.

    Time frame: 3 years

Secondary outcomes

  1. Assess the impact of malaria co-infections on mortality

    Number of deaths in children under 5 with malaria co-infection

    Time frame: 2 years

  2. Identify the underlying immunological mechanisms mediating malaria co-infections

    Concentration of cytokines IL6, IL1β and TNFα and IL 10 in children under 5 years of age

    Time frame: 2 years

  3. Identify epigenetic and transcriptomic modifications in infant, maternal and placental blood cells mediating malaria co-infections

    Expression level of transcripts according to the populations studied will be measured by RNA-seq

    Time frame: 2 years

  4. Identify molecules associated with epigenetic modifications (metabolome, proteome).

    Expression level of proteins and metabolites according to the populations studied will be measured by RNA-seq

    Time frame: 2 years

  5. Identify determinants of malaria co-infections and severe bacterial infections.

    The number of malaria co-infection events associated with severe bacterial infection in febrile children under 5 years of age.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.

Of 102 interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartEst.
Feb 15, 2025
Primary completionEst.
Feb 15, 2027
CompletionEst.
Aug 15, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06769815
Lead sponsor
Institut Pasteur
Collaborators
Institut de Recherche pour le Developpement
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Feb 15, 2025 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Bich-Tram Huynh, PhD
Contact
bich-tram.huynh@pasteur.fr
+33 1 53 55 18 50
Celia Dechavanne, PhD
Contact
celia.dechavanne@ird.fr
+229 99 35 05 98
Bich-Tram Huynh, PhD
study director · Institut Pasteur
Luc Douti, MD
principal investigator · CHU-Campus de Lomé
Serge Ekoué Gbadoe, MD
principal investigator · Hôpital de district Polyclinique de Zio-Tsévié

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion